Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 Apr 3;143(1):229–244.e9. doi: 10.1016/j.jaci.2018.03.007

Figure 4. IL-33 and leukotrienes synergistically promote the mRNA expression of IL-17 in ILC2.

Figure 4

(A and B) ILC2s from naïve wild-type mice and cultured in the presence of IL-7 for 24 h. Cells were stimulated without or with IL-33 for another 24 h or 72 h before collected for analysis. (C) Levels of LTC4 in lung tissues were analyzed by ELISA. Level of LTC4 normalized to weight of lung tissue was shown. Data are representative of two independent experiments. (D and E) ILC2s were purified from naïve wild-type mice and cultured with IL-7 for 24 h. Cells were then treated with or without IL-33 for 24 hr. In some groups, LTC4 (100nM) or LTD4 (100nM) was added for the last 4 h before cells were collected for analysis. (F) Cells were treated with IL-7, IL-33 and LTC4 in the presence or absence of inhibitors for NFAT, JNK, p38 and NF-κB. The expressions of IL-17 or IL-13 mRNA were normalized to control group (Mock) respectively. Relative IL-17 and IL-13 mRNA expression in fold compared to control group was shown. (D–F) Data are means+SEM. Data are representative of triplicates from one experiment. Experiments have been repeated for 3 times. (G) Mice were treated with CsA or FK506 before and during IL-33 injection. Expression of IL-17, IL-13, GATA3 gated on Lin− cells was analyzed by flow cytometry. (H and I) Percentages of IL-13+ and IL-17+ cells gated on ILC2s were shown. Data are means±SEM. Data are representative of two independent experiments.